2,834 results on '"COLORECTAL liver metastasis"'
Search Results
2. Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer (ARMANI)
- Author
-
KKS Dresden and German Cancer Research Center
- Published
- 2024
3. Assessment by a multidisciplinary team conference affects treatment strategy and overall survival in patients with synchronous colorectal liver metastases.
- Author
-
Almlöv, Karin, Arbman, Gunnar, Björnsson, Bergthor, Elander, Nils O., Hager, Jakob, Hamid, Salik, Landerholm, Kalle, Loftås, Per, and Sandström, Per
- Subjects
- *
COLORECTAL liver metastasis , *OVERALL survival , *LIVER surgery , *REGRESSION analysis , *MEDICAL care - Abstract
The aim of this retrospective observational study was to investigate the geographical or sex differences in patients with synchronous colorectal liver metastases (sCRLM) in terms of assessment by a multidisciplinary team conference (MDT), curative treatment, and overall survival. All sCRLM patients in the South-East Health Care Region of Sweden from 2009 to 2015 were included (n = 615). Data were derived from the Swedish Colorectal Cancer Registry, Swedish Registry of Liver and Bile Surgery and medical records. Patients who had a hepatobiliary unit (HBU) at the nearest hospital were more likely to undergo liver surgery (HBU+, 37% (n = 106), compared to HBU−, 22% (n = 60); p = 0.001) and had a better median survival (p < 0.001). No sex differences were observed. In multivariate Cox regression analyses of overall survival, assessment by an MDT that included a liver surgeon was independently linked to better survival (HR 0.574, 0.433–0.760). There were no sex differences in access to liver surgery or overall survival, however, there were geographical inequalities, where residency near a hospital with HBU was associated with increased overall survival and the possibility to receive liver surgery. Assessment at MDT with liver surgeon present was associated with greater survival, indicating its important role for treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Viscoelastic properties of colorectal liver metastases reflect tumour cell viability.
- Author
-
Skrip, Lisa-Marie, Moosburner, Simon, Tang, Peter, Guo, Jing, Görner, Steffen, Tzschätzsch, Heiko, Brüggemann, Kristin, Walter, Kilian Alexander, Hosse, Clarissa, Fehrenbach, Uli, Arnold, Alexander, Modest, Dominik, Krenzien, Felix, Schöning, Wenzel, Malinka, Thomas, Pratschke, Johann, Papke, Björn, Käs, Josef A., Sack, Ingolf, and Sauer, Igor M.
- Subjects
- *
COLORECTAL liver metastasis , *NEOADJUVANT chemotherapy , *CELL survival , *SHEAR waves , *NUCLEAR density - Abstract
Background: Colorectal cancer is the third most common tumour entity in the world and up to 50% of the patients develop liver metastases (CRLM) within five years. To improve and personalize therapeutic strategies, new diagnostic tools are urgently needed. For instance, biomechanical tumour properties measured by magnetic resonance elastography (MRE) could be implemented as such a diagnostic tool. We postulate that ex vivo MRE combined with histological and radiological evaluation of CRLM could provide biomechanics-based diagnostic markers for cell viability in tumours. Methods: 34 CRLM specimens from patients who had undergone hepatic resection were studied using ex vivo MRE in a frequency range from 500 Hz to 5300 Hz with increments of 400 Hz. Single frequency evaluation of shear wave speed and wave penetration rate as proxies for stiffness and viscosity was performed, along with rheological model fitting based on the spring-pot model and powerlaw exponent α, ranging between 0 (complete solid behaviour) and 1 (complete fluid behaviour). For histological analysis, samples were stained with H&E and categorized according to the degree of regression. Quantitative histologic analysis was performed to analyse nucleus size, aspect ratio, and density. Radiological response was assessed according to RECIST-criteria. Results: Five samples showed major response to chemotherapy, six samples partial response and 23 samples no response. For higher frequencies (> 2100 Hz), shear wave speed correlated significantly with the degree of regression (p ≤ 0.05) indicating stiffer properties with less viable tumour cells. Correspondingly, rheological analysis of α revealed more elastic-solid tissue properties at low cell viability and major response (α = 0.43 IQR 0.36, 0.47) than at higher cell viability and no response (α = 0.51 IQR 0.48, 0.55; p = 0.03). Quantitative histological analysis showed a decreased nuclear area and density as well as a higher nuclear aspect ratio in patients with major response to treatment compared to patients with no response (all p < 0.05). Discussion: Our results suggest that MRE could be useful in the characterization of biomechanical property changes associated with cell viability in CRLM. In the future, MRE could be applied in clinical diagnosis to support individually tailored therapy plans for patients with CRLM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. A Comparative Study of DC Beads, Callispheres and Multimodal Imaging Nano-Assembled Microspheres Loaded with Irinotecan in Vitro.
- Author
-
Wang, Jieyu, Zhang, Shaoya, He, Yiwei, Sun, Wan, Zhu, Xiaoyang, Xi, Zihan, Ma, Qian, Ye, Yuanxin, Song, Ziyang, Zhang, Yuqing, and Shao, Guoliang
- Subjects
COLORECTAL liver metastasis ,IRINOTECAN ,NONOPIOID analgesics ,CHEMOEMBOLIZATION - Abstract
Introduction: In recent years, the development of drug-eluting embolization beads that can be imaged has become a hot research topic in regard to meeting clinical needs. In our previous study, we successfully developed nano-assembled microspheres (NAMs) for multimodal imaging purposes. NAMs can not only be visualized under CT/MR/Raman imaging but can also load clinically required doses of doxorubicin. It is important to systematically compare the pharmacokinetics of NAMs with those of commercially available DC Beads and CalliSpheres to evaluate the clinical application potential of NAMs. Methods: In our study, we compared NAMs with two types of drug-eluting beads (DEBs) in terms of irinotecan, drug-loading capacity, release profiles, microsphere diameter variation, and morphological characteristics. Results: Our results indicate that NAMs had an irinotecan loading capacity similar to those of DC Beads and CalliSpheres but exhibited better sustained release in vitro. Conclusion: NAMs have great potential for application in transcatheter arterial chemoembolization for the treatment of colorectal cancer liver metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Genetic alteration of SLCO1B3 defines constitutional indocyanine green excretory defect in patients who underwent hepatectomy.
- Author
-
Tanimoto, Meguri, Nishioka, Yujiro, Inagaki, Yoshinori, Kokudo, Takashi, Ishizawa, Takeaki, Arita, Junichi, Akamatsu, Nobuhisa, Kaneko, Junichi, and Hasegawa, Kiyoshi
- Subjects
- *
COLORECTAL liver metastasis , *GENE expression , *HEPATIC fibrosis , *INDOCYANINE green , *SERUM albumin - Abstract
Aim Methods Results Conclusions Constitutional indocyanine green (ICG) excretory defects must be distinguished when assessing liver function. The absence of OATP1B3 expression due to homogenous alterations in the
SLCO1B3 gene has been recently reported to induce ICG excretory defects; however, its association with the clinical examinations and the clinical implications of heterogeneousSLCO1B3 gene alteration remain unclear.OATP1B3 expression was evaluated in 49 patients who underwent hepatectomy after evaluation of the ICG retention rate at 15 min (ICGR15) and technetium‐99 m‐galactosyl serum albumin (99mTc‐GSA) hepatic scintigraphy. Additionally, alterations inSLCO1B3 were analyzed in patients without OATP1B3 expression. Subsequently, 59 patients who underwent hepatectomy for colorectal liver metastasis (CRLM) were analyzed.Of 49 patients, 6 (12%) had absent OATP1B3 expression. They had significantly higher ICGR15 value (74.7% vs. 23.5%;p < 0.0001), better modified albumin–bilirubin (ALBI) grade (≤grade 2A, 100% vs. 42%;p = 0.010), more normal 99mTc‐GSA hepatic scintigraphy (100% vs. 28%;p = 0.0003), and better pathological liver fibrosis (F0–1, 100% vs. 49%;p = 0.027) compared to those with OATP1B3 expression. Three available frozen blocks of cases without OATP1B3 expression showed homozygous alterations inSLCO1B3 . Of 59 patients with CRLM in normal liver background, five (8.5%) had heterozygous insertion inSLCO1B3 , however they had no difference in ICGR15 values or other clinical findings compared to the other patients.Constitutional ICG excretory defects may be defined by the complete absence of OATP1B3 expression. The modified ALBI grade and 99mTc‐GSA hepatic scintigraphy were useful for detecting constitutional ICG excretory defects. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
7. RETRACTED: LncRNA BLACAT1 Accelerates Non-small Cell Lung Cancer Through Up-Regulating the Activation of Sonic Hedgehog Pathway.
- Subjects
NON-small-cell lung carcinoma ,CANCER genetics ,NUCLEIC acid hybridization ,COLORECTAL liver metastasis ,WNT/BETA-catenin pathway ,COLONY-forming units assay - Abstract
This article explores the role of a long non-coding RNA called BLACAT1 in the progression of non-small cell lung cancer (NSCLC). The study found that BLACAT1 expression was significantly increased in lung cancer tissues compared to healthy tissues, and that high expression of BLACAT1 promoted the growth and progression of lung cancer cells. Additionally, BLACAT1 was found to activate the Sonic Hedgehog signaling pathway, which is involved in cancer progression. The findings suggest that BLACAT1 may be a potential target for the treatment of NSCLC. It is important to note that this article has been retracted. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
8. A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastases.
- Author
-
Yunlin Jiang, Taihang Shao, Mingye Zhao, Yahong Xue, and Xueping Zheng
- Subjects
COLORECTAL liver metastasis ,BAYESIAN analysis ,COMBINATION drug therapy ,OVERALL survival ,PROGRESSION-free survival - Abstract
Background: Evidence comparing the efficacy of different treatments for patients with unresectable colorectal liver metastases (CRLM) receiving firstline or maintenance therapy is sparse. We aimed to assess the efficacy and safety of these treatments, with a distinct focus on evaluating first-line and maintenance treatments separately. Methods: We conducted Bayesian network meta-analyses, sourcing Englishlanguage randomized controlled trials (RCTs) published through July 2023 from databases including PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, and key conference proceedings. Phase â...¡ or â...¢ trials that assessed two or more therapeutic regimens were included. Primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), objective response rate (ORR), adverse events graded as 3 or above (SAE), and R0 liver resection rate. Hazards Ratios (HRs) and 95% confidence intervals (CI) were used as effect size for OS and PFS, Odds Ratios (ORs) and 95% CI were used for ORR, SAEs and R0 resection rate. Subgroup and sensitive analyses were conducted to analysis the model uncertainty (PROSPERO: CRD42023420498). Results: 56 RCTs were included (50 for first-line treatment, six for maintenance therapies), with a total of 21,323 patients. Regarding first-line, for OS, the top three mechanisms were: local treatment + single-drug chemotherapy (SingleCT), Targeted therapy (TAR)+SingleCT, and TAR + multi-drug chemotherapy (MultiCT). Resection or ablation (R/A)+SingleCT, S1, and Cetuximab + intensified fluorouracil-based combination chemotherapy (ICTFU) were identified as the best treatments. For PFS, the top three mechanisms were: Immune therapy + TAR + MultiCT, multi-targeted therapy (MultiTAR), TAR + SingleCT. The top three treatments were: Atezolizumab + Bevacizumab + fluorouracil-based combination chemotherapy (CTFU), TAS-102+bevacizumab, Bevacizumab + ICTFU. Cetuximab + CTFU was the best choice for RAS/RAF wild-type patients. Regarding maintenance treatment, Bevacizumab + SingleCT and Adavosertib were the best options for OS and PFS, respectively. For safety, MultiCT was the safest, followed by local treatment + MultiCT, TAR + MultiCT caused the most SAEs. Bevacizumab plus chemotherapy was found to be the safest among all targeted combination therapies. Conclusion: In first-line, local treatment or targeted therapsy plus chemotherapy are the best mechanisms. R/A + SingleCT or CTFU performed the best for OS, Atezolizumab + Bevacizumab + ICTFU was the best option regarding PFS. For RAS/RAF wild-type patients, Cetuximab + CTFU was the optimal option. Monotherapy may be preferred choice for maintenance treatment. Combination therapy resulted in more SAEs when compared to standard chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Baseline hepatobiliary MRI for predicting chemotherapeutic response and prognosis in initially unresectable colorectal cancer liver metastases.
- Author
-
Chen, Yazheng, Lu, Tao, Zhang, Yongchang, Li, Hang, Xu, Jingxu, and Li, Mou
- Subjects
- *
COLORECTAL liver metastasis , *RECEIVER operating characteristic curves , *RADIOMICS , *PROGRESSION-free survival , *TREATMENT effectiveness - Abstract
Purpose: To evaluate the performance of hepatobiliary MRI parameters as predictors of clinical response to chemotherapy in patients with initially unresectable colorectal cancer liver metastases (CRLM). Methods: Eighty-five patients with initially unresectable CRLM were retrospectively enrolled from two hospitals and scanned using gadobenate dimeglumine-enhanced MRI before treatment. Therapy response was evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Conventional parameters (i.e., signal intensity [SI]) and radiomics features of portal venous phase (PVP) and hepatobiliary phase (HBP) images were analyzed between the responders and non-responders. Next, the combined model was constructed, and the area under the receiver operating characteristic (ROC) curve (AUC) was calculated. The relationship between the combined model and progression-free survival (PFS) was analyzed using Cox regression. Results: Of the 85 patients from two hospitals, 42 were in the response group, and 43 were in the non-response group. Upon conducting five-fold cross-validation, the normalized relative enhancement (NRE) of CRLM during the PVP yielded an AUC of 0.625. Additionally, a radiomics feature derived from the tumor area in the HBP achieved an AUC of 0.698, while a separate feature extracted from the peritumoral region in the HBP recorded an AUC of 0.709. The model that integrated these three features outperformed the individual features, achieving an AUC of 0.818. Furthermore, the combined model exhibited a significant correlation with PFS (P < 0.001). Conclusion: The combined model, based on baseline hepatobiliary MRI, aids in predicting chemotherapeutic response and PFS in patients with initially unresectable CRLM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Machine learning-based screening and validation of liver metastasis-specific genes in colorectal cancer.
- Author
-
Zheng, Shiyao, He, Hongxin, Zheng, Jianfeng, Zhu, Xingshu, Lin, Nan, Wu, Qing, Wei, Enhao, Weng, Caiming, Chen, Shuqian, Huang, Xinxiang, Jian, Chenxing, Guan, Shen, and Yang, Chunkang
- Subjects
- *
DISEASE risk factors , *COLORECTAL liver metastasis , *MACHINE learning , *PROGNOSIS , *CANCER genes - Abstract
Colorectal liver metastasis (CRLM) is challenging in the clinical treatment of colorectal cancer. Limited research has been conducted on how CRLM develops. RNA sequencing data were obtained from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). Four machine learning algorithms were used to screen the hub CRLM-specific genes, including Least Absolute Shrinkage and Selection Operator (Lasso), Random forest, SVM-RFE, and XGboost. The model for identifying CRLM was developed using stepwise logistic regression and was validated using internal and independent datasets. The prognostic value of hub CRLM-specific genes was assessed using the Lasso-Cox method. The in vitro experiments were performed using SW620 cells. The CRLM identification model was developed based on four CRLM-specific genes (SPP1, ZG16, P2RY14, and PRKAR2B), and the model efficacy was validated using GSE41258 and three external cohorts. Five CRLM-specific prognostic hub genes, SPP1, ZG16, P2RY14, CYP2E1, and C5, were identified using the Lasso-Cox algorithm, and a risk score was constructed. The risk score was validated using the GSE39582 cohort. Three genes have both efficacy in identifying CRLM and prognostic value: ZG16, P2RY14, and SPP1. Immune infiltration and enrichment analyses demonstrated that SPP1 was associated with M2 macrophage polarization and extracellular matrix remodeling. In vitro experiments indicated that SPP1 may act as a cancer-promoting factor. The hub CRLM-specific gene SPP1 can help determine the diagnosis, prognosis, and immune infiltration of patients with CRLM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. SLC14A1 and TGF-β signaling: a feedback loop driving EMT and colorectal cancer metachronous liver metastasis.
- Author
-
Zhang, Yixun, Yang, Yumeng, Qi, Xuan, Cui, Peng, Kang, Yi, Liu, Haiyi, Wei, Zhigang, and Wang, Haibo
- Subjects
- *
COLORECTAL liver metastasis , *LIVER metastasis , *GENE expression - Abstract
Background: Colorectal cancer (CRC) metachronous liver metastasis is a significant clinical challenge, largely attributable to the late detection and the intricate molecular mechanisms that remain poorly understood. This study aims to elucidate the role of Solute Carrier Family 14 Member 1 (SLC14A1) in the pathogenesis and progression of CRC metachronous liver metastasis. Methods: We conducted a comprehensive analysis of CRC patient data from The Cancer Genome Atlas and GSE40967 databases, focusing on the differential expression of genes associated with non-metachronous liver metastasis and metachronous liver metastasis. Functional assays, both in vitro and in vivo, were performed to assess the biological impact of SLC14A1 modulation in CRC cells. Gene set enrichment analysis, molecular assays and immunohistochemical analyses on clinical specimens were employed to unravel the underlying mechanisms through which SLC14A1 exerts its effects. Results: SLC14A1 was identified as a differentially expressed gene, with its overexpression significantly correlating with poor relapse-free and overall survival. Mechanistically, elevated SLC14A1 levels enhanced CRC cell invasiveness and migratory abilities, corroborated by upregulated TGF-β/Smad signaling and Epithelial-Mesenchymal Transition. SLC14A1 interacted with TβRII and stabilized TβRII protein, impeding its Smurf1-mediated K48-linked ubiquitination and degradation, amplifying TGF-β/Smad signaling. Furthermore, TGF-β1 reciprocally elevated SLC14A1 mRNA expression, with Snail identified as a transcriptional regulator, binding downstream of SLC14A1's transcription start site, establishing a positive feedback loop. Clinically, SLC14A1, phosphorylated Smad2, and Snail were markedly upregulated in CRC patients with metachronous liver metastasis, underscoring their potential as prognostic markers. Conclusions: Our findings unveil SLC14A1 as a critical regulator in CRC metachronous liver metastasis, providing novel insights into the molecular crosstalk between SLC14A1 and TGF-β/Smad signaling. These discoveries not only enhance our understanding of CRC metachronous liver metastasis pathogenesis, but also highlight SLC14A1 as a promising target for therapeutic intervention and predictive marker. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Laparoscopic versus open liver resection for colorectal liver metastasis: an umbrella review.
- Author
-
Pinto, Federico, Pangrazio, MarcoDi, Martinino, Alessandro, Todeschini, Letizia, Toti, Francesco, Cristin, Luca, Caimano, Miriam, Mattia, Amelia, Bianco, Giuseppe, Spoletini, Gabriele, and Giovinazzo, Francesco
- Subjects
COLORECTAL liver metastasis ,MINIMALLY invasive procedures ,SURGICAL blood loss ,LAPAROSCOPIC surgery ,CANCER relapse ,LIVER surgery - Abstract
Introduction: This study comprehensively compared laparoscopic liver resection (LLR) to open liver resection (OLR) in treating colorectal cancer liver metastasis (CRLM). Methods: A systematic review of relevant literature was conducted to assess a range of crucial surgical and oncological outcomes. Results: Findings indicate that minimally invasive surgery (MIS) did not significantly prolong the duration of surgery compared to open liver resection and notably demonstrated lower blood transfusion rates and reduced intraoperative blood loss. While some studies favored MIS for its lower complication rates, others did not establish a statistically significant difference. One study identified a lower post-operative mortality rate in the MIS group. Furthermore, MIS consistently correlated with shorter hospital stays, indicative of expedited post-operative recovery. Concerning oncological outcomes, while certain meta-analyses reported a lower rate of cancer recurrence in the MIS group, others found no significant disparity. Overall survival and disease-free survival remained comparable between the MIS and open liver resection groups. Conclusion: The analysis emphasizes the potential advantages of LLR in terms of surgical outcomes and aligns with existing literature findings in this field. Systematic review registration: [website], identifier [registration number]. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Establishment of nomogram to predict overall survival and cancer-specific survival of local tumor resection in patients with colorectal cancer liver metastasis with unresectable metastases: a large population-based analysis.
- Author
-
Hou, Songlin, Li, Lifa, Hou, Huafang, Zhou, Tong, and Zhou, He
- Subjects
COLORECTAL liver metastasis ,PROGNOSIS ,DECISION making ,RECEIVER operating characteristic curves ,OVERALL survival ,CLINICAL prediction rules - Abstract
Background and Purpose: The tumour-node metastasis (TNM) classification is a common model for evaluating the prognostic value of tumour patients. However, few models have been used to predict the survival outcomes of patients with colorectal cancer liver metastasis (CRLM) with unresectable metastases who received the primary local surgery. Thus, we utilized the Surveillance, Epidemiology, and End Results (SEER) database to establish novel nomograms for predicting the overall survival (OS) and cancer-specific survival (CSS) of these patients. Methods: Extracted primary data on CRLM patients by local surgery from SEER database. All prognostic factors of OS and CSS were determined by Cox regression analysis. The concordance index (C-index), receiver operating characteristic (ROC) curves and calibration curves were used to further evaluate the accuracy and discrimination of these nomograms. Decision curve analysis (DCA) was executed to evaluate the nomograms for the clinical net benefit. Risk stratification analysis (RSA) was used to evaluate the reliability of them in clinical. Results: 3622 eligible patients were screened and assigned to training cohort (1812) or validation cohort (1810). The age, chemotherapy, tumour grade, primary tumour site, tumour size, lymph node positive rate (LNR), marital status, and carcinoembryonic antigen (CEA) were independent prognostic factors of OS. Additionally, the age, chemotherapy, tumour grade, primary tumour site, tumour size, LNR, and CEA were independent prognostic factors of CSS. The results of C-indexes and ROC curves indicated that the established nomograms exhibited better discrimination power than TNM classification. The calibration curves demonstrated excellent agreement between the predicted and actual survival rates for 1-, 3-, and 5 year OS and CSS. Meanwhile, the validation cohort demonstrated similar results. Background the clinic context, the DCA showed that these nomograms have higher net benefits, and the RSA showed that patients were further divided into low risk, medium risk, and high risk groups according to the predicted scores from nomograms. And, the Kaplan–Meier curve and log-rank test showed that the survival differences among the three groups are statistically significant. Conclusions: The prognostic nomograms showed very high accuracy, identifiability, and clinical practicality in predicting the OS and CSS of CRLM patients with unresectable metastases treated by local surgery at 1-, 3-, and 5 years, which might improve individualized predictions of survival risks and help clinicians formulate treatment plans. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Colorectal cancer.
- Author
-
Eng, Cathy, Yoshino, Takayuki, Ruíz-García, Erika, Mostafa, Nermeen, Cann, Christopher G, O'Brian, Brittany, Benny, Amala, Perez, Rodrigo O, and Cremolini, Chiara
- Subjects
- *
COLORECTAL liver metastasis , *COLORECTAL cancer , *GUT microbiome , *MOLECULAR oncology , *OVERALL survival - Abstract
Despite decreased incidence rates in average-age onset patients in high-income economies, colorectal cancer is the third most diagnosed cancer in the world, with increasing rates in emerging economies. Furthermore, early onset colorectal cancer (age ≤50 years) is of increasing concern globally. Over the past decade, research advances have increased biological knowledge, treatment options, and overall survival rates. The increase in life expectancy is attributed to an increase in effective systemic therapy, improved treatment selection, and expanded locoregional surgical options. Ongoing developments are focused on the role of sphincter preservation, precision oncology for molecular alterations, use of circulating tumour DNA, analysis of the gut microbiome, as well as the role of locoregional strategies for colorectal cancer liver metastases. This overview is to provide a general multidisciplinary perspective of clinical advances in colorectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Comparison of systemic treatments for previously treated patients with unresectable colorectal liver metastases: a systematic review and network meta-analysis.
- Author
-
Yunlin Jiang, Mingye Zhao, Wenxi Tang, and Xueping Zheng
- Subjects
COLORECTAL liver metastasis ,CLINICAL trials ,COMBINATION drug therapy ,BAYESIAN analysis ,RANDOMIZED controlled trials - Abstract
Background: There is limited evidence of comparative results among different treatments for patients with unresectable colorectal liver metastases (CRLM) who have failed at least one line of previous systemic therapy. We aimed to compare the efficacy of systemic treatments among these patients through this investigation. Methods: We collected randomized controlled trials (RCTs) reported in English up until July 2023, from databases including PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and prominent conference databases, for this Bayesian network meta-analysis. Phase II or III trials that evaluated at least two therapeutic regimens were included. Primary outcome was overall survival (OS), secondary outcome was progression-free survival (PFS). Hazards ratios (HRs) with 95% confidence intervals (CIs) were used as effect size. Subgroup analysis was performed based on metastatic sites. The current systematic review protocol was registered on PROSPERO (CRD42023420498). Results: 30 RCTs were included, with a total of 13,511 patients. Compared to chemotherapy, multi-targeted therapy (HR 0.57, 95% CI 0.37-0.87) and targeted therapy plus chemotherapy (HR 0.78, 95% CI 0.67-0.91) show significant advantages. Targeted therapy (HR 0.92, 95% CI 0.54-1.57) and local treatment plus chemotherapy (HR 1.03, 95% CI 0.85-1.23) had comparable performance. For patients with liver metastases, TAS-102 plus bevacizumab, aflibercept plus fluorouracil-based combination chemotherapy (CTFU), and bevacizumab plus capecitabine-based combination chemotherapy (CTCA) showed the best outcomes in terms of OS. Bevacizumab plus intensified CTFU, bevacizumab plus CTCA, and HAI followed by single-agent chemotherapy (SingleCT) performed the best regarding PFS. For patients with liver-limited metastases, aflibercept plus CTFU is the optimal choice in OS. For PFS, the best options were HAI followed by SingleCT, aflibercept plus CTFU, and panitumumab plus CTFU. For patients with multiple-site metastases, the best treatments were TAS-102 plus bevacizumab, bevacizumab plus CTCA, bevacizumab plus CTFU, and aflibercept plus CTFU. Conclusion: Multi-targeted therapy and targeted therapy plus chemotherapy are the best treatment mechanisms. TAS-102 plus bevacizumab is superior in OS, the combination of anti-VEGF drugs like bevacizumab and aflibercept with standard chemotherapy is the preferred option for CRLM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Radiomic Gradient in Peritumoural Tissue of Liver Metastases: A Biomarker for Clinical Practice? Analysing Density, Entropy, and Uniformity Variations with Distance from the Tumour.
- Author
-
Fiz, Francesco, Ragaini, Elisa Maria, Sirchia, Sara, Masala, Chiara, Viganò, Samuele, Francone, Marco, Cavinato, Lara, Lanzarone, Ettore, Ammirabile, Angela, and Viganò, Luca
- Subjects
- *
COLORECTAL liver metastasis , *LIVER tumors , *SURGICAL margin , *COMPUTED tomography , *ONCOLOGIC surgery - Abstract
The radiomic analysis of the tissue surrounding colorectal liver metastases (CRLM) enhances the prediction accuracy of pathology data and survival. We explored the variation of the textural features in the peritumoural tissue as the distance from CRLM increases. We considered patients with hypodense CRLMs >10 mm and high-quality computed tomography (CT). In the portal phase, we segmented (1) the tumour, (2) a series of concentric rims at a progressively increasing distance from CRLM (from one to ten millimetres), and (3) a cylinder of normal parenchyma (Liver-VOI). Sixty-three CRLMs in 51 patients were analysed. Median peritumoural HU values were similar to Liver-VOI, except for the first millimetre around the CRLM. Entropy progressively decreased (from 3.11 of CRLM to 2.54 of Liver-VOI), while uniformity increased (from 0.135 to 0.199, p < 0.001). At 10 mm from CRLM, entropy was similar to the Liver-VOI in 62% of cases and uniformity in 46%. In small CRLMs (≤30 mm) and responders to chemotherapy, normalisation of entropy and uniformity values occurred in a higher proportion of cases and at a shorter distance. The radiomic analysis of the parenchyma surrounding CRLMs unveiled a wide halo of progressively decreasing entropy and increasing uniformity despite a normal radiological aspect. Underlying pathology data should be investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. 6,126 hepatectomies in 2022: current trend of outcome in Italy.
- Author
-
Nicolazzi, Marco, Di Martino, Marcello, Baroffio, Paolo, and Donadon, Matteo
- Subjects
- *
LIVER surgery , *HOSPITAL mortality , *OPERATIVE surgery , *COLORECTAL liver metastasis , *LIVER tumors - Abstract
Purpose: Whether hospital volume affects outcome of patients undergoing hepatobiliary surgery, and whether the centralization of such procedures is justified remains to be investigated. The aim of this study was to analyze the outcome of liver surgery in Italy in relationship of hospital volume. Methods: This is a nationwide retrospective observational study conducted on data collected by the National Italian Registry "Piano Nazionale Esiti" (PNE) 2023 that included all liver procedures performed in 2022. Outcome measure were case volume and 30-day mortality. Hospitals were classified as very high-volume (H-Vol), intermediate-volume (I-Vol), low-volume (L-Vol) and very low-volume (VL-VoL). A review on centralization process and outcome measures was added. Results: 6,126 liver resections for liver tumors were performed in 327 hospitals in 2022. The 30-day mortality was 2.2%. There were 14 H-Vol, 19 I-Vol, 31 L-Vol and 263 VL-Vol hospitals with 30-day mortality of 1.7%, 2.2%, 2.6% and 3.6% respectively (P < 0.001); 220 centers (83%) performed less than 10 resections, and 78 (29%) centers only 1 resection in 2022. By considering the geographical macro-areas, the median count of liver resection performed in northern Italy exceeded those in central and southern Italy (57% vs. 23% vs. 20%, respectively). Conclusions: High-volume has been confirmed to be associated to better outcome after hepatobiliary surgical procedures. Further studies are required to detail the factors associated with mortality. The centralization process should be redesigned and oversight. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. miR-455/GREM1 axis promotes colorectal cancer progression and liver metastasis by affecting PI3K/AKT pathway and inducing M2 macrophage polarization.
- Author
-
Dai, Shipeng, Xu, Fan, Xu, Xiaozhang, Huang, Tian, Wang, Yiming, Wang, Hongyu, Xie, Yucheng, Yue, Lei, Zhao, Wenhu, Xia, Yongxiang, Gu, Jian, and Qian, Xiaofeng
- Subjects
- *
COLORECTAL liver metastasis , *PI3K/AKT pathway , *INTESTINAL cancer , *LIVER metastasis , *TISSUE differentiation - Abstract
Background: Colorectal cancer is among the most common malignant tumors affecting the gastrointestinal tract. Liver metastases, a complication present in approximately 50% of colorectal cancer patients, are a considerable concern. Recently, studies have revealed the crucial role of miR-455 in tumor pathogenesis. However, the effect of miR-455 on the progression of liver metastases in colorectal cancer remains controversial. As an antagonist of bone morphogenetic protein(BMP), Gremlin 1 (GREM1) may impact organogenesis, body patterning, and tissue differentiation. Nevertheless, the role of miR-455 in regulating GREM1 in colorectal cancer liver metastases and how miR-455/GREM1 axis influences tumour immune microenvironment is unclear. Methods: Bioinformatics analysis shows that miR-455/GREM1 axis plays crucial role in liver metastasis of intestinal cancer and predicts its possible mechanism. To investigate the impact of miR-455/GREM1 axis on the proliferation, invasion, and migration of colorectal cancer cells, colony formation assay, wound healing and transwell assay were examined in vitro. The Dual-Luciferase reporter gene assay and RNA pull-down assay confirmed a possible regulatory effect between miR-455 and GREM1. In vivo, colorectal cancer liver metastasis(CRLM) model mice was established to inquiry the effect of miR-455/GREM1 axis on tumor growth and macrophage polarization. The marker of macrophage polarization was tested using immunofluorescence(IF) and quantitative real-time polymerase chain reaction(qRT-PCR). By enzyme-linked immunosorbent assay (ELISA), cytokines were detected in culture medium supernatants. Results: We found that miR-455 and BMP6 expression was increased and GREM1 expression was decreased in liver metastase compared with primary tumor. miR-455/GREM1 axis promotes colorectal cancer cells proliferation, migration, invasion via affected PI3K/AKT pathway. Moreover, downregulating GREM1 augmented BMP6 expression in MC38 cell lines, inducing M2 polarization of macrophages, and promoting liver metastasis growth in CRLM model mice. Conclusion: These data suggest that miR-455/GREM1 axis promotes colorectal cancer progression and liver metastasis by affecting PI3K/AKT pathway and inducing M2 macrophage polarization. These results offer valuable insights and direction for future research and treatment of CRLM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial.
- Author
-
Martinelli, Erika, Ciardiello, Davide, Martini, Giulia, Napolitano, Stefania, Del Tufo, Sara, D'Ambrosio, Luca, De Chiara, Marco, Famiglietti, Vincenzo, Nacca, Valeria, Cardone, Claudia, Avallone, Antonio, Cremolini, Chiara, Pietrantonio, Filippo, Maiello, Evaristo, Granata, Vincenza, Troiani, Teresa, Cappabianca, Salvatore, Ciardiello, Fortunato, Nardone, Valerio, and Reginelli, Alfonso
- Subjects
- *
IRINOTECAN , *COLORECTAL liver metastasis , *PROGRESSION-free survival , *METASTASIS , *CIRCULATING tumor DNA , *LIVER metastasis , *OVERALL survival - Abstract
Background: CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with RAS wild type (wt) metastatic colorectal cancer (mCRC). Objective: We conducted a post hoc analysis to identify potential radiomic biomarkers for patients with CRC liver metastasis (LM). Patients and Methods: Patients with LM that could be measured by enhanced contrast phase computed tomography (CT) imaging at baseline and at first response evaluation were included. Multiple texture parameters were extracted with the LifeX Software. Delta-texture (D-TA) variations were calculated by comparing data at baseline and after treatment. Results: Overall, 55/77 patients (71%) had LM; 39 met the inclusion criteria for the current analysis. The D-TA parameters that significantly correlated at univariate analysis with median progression-free survival (mPFS) were EntropyHistogram (p = 0.021), HomogeneityGLCM (p < 0.001) and Dissimilarity GLCM (p = 0.002). At multivariate analysis, only HomogeneityGLCM resulted significant for PFS (p = 0.001). Patients (19/39, 48.7%) with reduction of HomogeneityGLCM experienced better mPFS (4.6 vs 2.9 months; HR 0.45; 95% CI 0.23–0.88; p = 0.021) and median overall survival (mOS) (17.3 vs 6.8 months; HR 0.40, 95% CI 0.21–0.80; p = 0.010). A trend to better mPFS, was also observed in patients with RAS/BRAF wt circulating tumor DNA and reduction of HomogeneityGLCM. Overall survival was significantly better in this subgroup of patients with low HomogeneityGLCM: mOS was 17.8 (95% CI 15.5–20.2) versus 6.8 months (95% CI 3.6–10.0) (HR 0.34, 95% CI 0.14–0.81; p = 0.016). Conclusion: Reduction in the D-TA parameter HomogeneityGLCM by radiomic analysis correlates with improved outcomes in patients with LM receiving cetuximab rechallenge plus avelumab therapy. Larger prospective studies are needed to validate and confirm these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Robotic surgery in stage IV rectal cancer: Ultra‐low anterior resection with TTSS anastomosis and hepatectomy – A video vignette.
- Author
-
Alsourani, Adnan, Colombari, Renan Carlo, Sánchez‐Rodríguez, María, Sánchez, Enrique Velasco, Zorita, Benjamin Díaz, Gómez, Luis Miguel Jiménez, Dujovne Lindenbaum, Paula, and Tejedor, Patricia
- Subjects
- *
RECTAL cancer , *RECTAL surgery , *SURGICAL robots , *SURGICAL anastomosis , *COLORECTAL liver metastasis , *HEPATECTOMY - Abstract
This article discusses the use of robotic surgery in the treatment of stage IV rectal cancer with liver metastases. The simultaneous robotic-assisted approach for both the primary tumor and synchronous liver lesions is shown to be a feasible and safe strategy. The article presents a case study of a 66-year-old female patient who underwent a robotic approach for both the rectal cancer and liver lesion. The procedure involved strategic trocar placement, parenchymal transection of the liver, pelvic dissection, and anastomosis. The patient had a successful postoperative course with clear margins and R0 resection of the liver metastasis. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
21. Cilostazol improves the prognosis after hepatectomy in rats with sinusoidal obstruction syndrome.
- Author
-
Sugita, Hiroaki, Nakanuma, Shinichi, Munesue, Seiichi, Ishikawa, Tatsuya, Tokoro, Tomokazu, Takei, Ryohei, Okazaki, Mitsuyoshi, Kato, Kaichiro, Takada, Satoshi, Makino, Isamu, Ozaki, Noriyuki, Yamamoto, Yasuhiko, and Yagi, Shintaro
- Subjects
- *
HEPATIC veno-occlusive disease , *HEPATECTOMY , *COLORECTAL liver metastasis , *LABORATORY rats , *RATS - Abstract
Background and Aim: Safe radical hepatectomy is important for patients with colorectal liver metastases complicated by sinusoidal obstruction syndrome (SOS) after oxaliplatin‐based chemotherapy. This study aimed to investigate the impact of preoperative administration of cilostazol (CZ), an oral selective phosphodiesterase III inhibitor, on hepatectomy in rat SOS model. Material and Methods: Rats were divided into NL (normal liver), SOS (monocrotaline [MCT]‐treated), and SOS + CZ (MCT + CZ‐treated) groups. MCT or CZ was administered orally, and a 30% partial hepatectomy was performed 48 h after MCT administration. Postoperative survival rates were evaluated (n = 9, for each). Other rats were sacrificed on postoperative days (POD) 1 and 3 and evaluated histologically, immunohistochemically, biochemically, and using transmission electron microscopy (TEM), focusing particularly on SOS findings, liver damage, and liver sinusoidal endothelial cell (LSEC) injury. Results: The cumulative 10‐day postoperative survival rate was significantly higher in the SOS + CZ group than in the SOS group (88.9% vs 33.3%, P = 0.001). Total SOS scores were significantly lower in the SOS + CZ group than in the SOS group on both POD 1 and 3. Serum biochemistry and immunohistochemistry showed that CZ reduced liver damage after hepatectomy. TEM revealed that LSECs were significantly preserved morphologically in the SOS + CZ group than in the SOS group on POD 1 (86.1 ± 8.2% vs 63.8 ± 9.3%, P = 0.003). Conclusion: Preoperative CZ administration reduced liver injury by protecting LSECs and improved the prognosis after hepatectomy in rats with SOS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. CT versus MR guidance for radiofrequency ablation in patients with colorectal liver metastases: a 10-year follow-up favors MR guidance.
- Author
-
Pereira, Philippe Lucien, Siemou, Panagiota, Rempp, Hans-Jörg, Hoffmann, Rüdiger, Hoffmann, Ralf Thorsten, Kettenbach, Joachim, Clasen, Stephan, and Helmberger, Thomas
- Subjects
- *
COLORECTAL liver metastasis , *CATHETER ablation , *CANCER relapse , *TREATMENT effectiveness , *VIRTUAL colonoscopy , *MULTIDETECTOR computed tomography - Abstract
Objectives: To compare the results of CT- vs MR-guided radiofrequency ablation (RFA) of liver metastases (LM) from colorectal cancer after 10 years of follow-up in an observational, retrospective, and multicentric study. Methods: A total of 238 patients with 496 LM were treated with RFA either with CT (CT group) or magnetic resonance (MR group) guidance. Every ablated LM was assessed and followed up with diagnostic MRI. Technical success, technique efficacy, predictive factors, recurrence rates, and overall survival were assessed. Results: The CT group comprised 143 patients and the MR group 77 patients. Eighteen patients underwent ablation with both modalities. Technical success per patient and per lesion was 88% and 93% for CT and 87% and 89.6% for MR, and technique efficacy was 97.1% and 98.6% for CT and 98.7% and 99.3% for MR respectively. Local recurrence following the first ablation (primary patency) occurred in 20.1% (CT) vs 4.6% (MR) (p < 0.001). Residual liver tumor, size of LM, and advanced N and M stage at initial diagnosis were independent predictors for overall survival in both groups. The median overall survival measured from first RFA treatment was 2.6 years. The 1-year, 5-year, and 10-year survival were 85.9%, 25.5%, and 19.1% respectively. Conclusions: The MR group had significantly better local control compared to the CT group. There was no significant difference in patient survival between the two groups. Clinical relevance statement: MR-guided radiofrequency ablation of colorectal liver metastases is safe and effective, and offers better local control than CT-guided ablation. Key Points: • Imaging modality for radiofrequency ablation guidance is an independent predictor of local recurrence in colorectal liver metastases. • MR-guided radiofrequency ablation achieved better local control of liver metastases from colorectal cancer than CT-guided. • The number and size of liver metastases are, among others, independent predictors of survival. Radiofrequency ablation with MR guidance improved clinical outcome but does not affect survival. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. KHK-A promotes fructose-dependent colorectal cancer liver metastasis by facilitating the phosphorylation and translocation of PKM2.
- Author
-
Peng, Chaofan, Yang, Peng, Zhang, Dongsheng, Jin, Chi, Peng, Wen, Wang, Tuo, Sun, Qingyang, Chen, Zhihao, Feng, Yifei, and Sun, Yueming
- Subjects
COLORECTAL liver metastasis ,WARBURG Effect (Oncology) ,ALTERNATIVE RNA splicing ,LIVER metastasis ,PHOSPHORYLATION - Abstract
Excessive fructose diet is closely associated with colorectal cancer (CRC) progression. Nevertheless, fructose's specific function and precise mechanism in colorectal cancer liver metastasis (CRLM) is rarely known. Here, this study reported that the fructose absorbed by primary colorectal cancer could accelerate CRLM, and the expression of KHK-A, not KHK-C, in liver metastasis was higher than in paired primary tumors. Furthermore, KHK-A facilitated fructose-dependent CRLM in vitro and in vivo by phosphorylating PKM2 at Ser37. PKM2 phosphorylated by KHK-A inhibited its tetramer formation and pyruvic acid kinase activity but promoted the nuclear accumulation of PKM2. EMT and aerobic glycolysis activated by nuclear PKM2 enhance CRC cells' migration ability and anoikis resistance during CRLM progression. TEPP-46 treatment, targeting the phosphorylation of PKM2, inhibited the pro-metastatic effect of KHK-A. Besides, c-myc activated by nuclear PKM2 promotes alternative splicing of KHK-A, forming a positive feedback loop. Upregulated KHK-A promoted the phosphorylation and nuclear translocation of PKM2 in colorectal cancer. Nuclear PKM2 promoted EMT, aerobic glycolysis, CRLM and alternative splicing of KHK-A. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Association between Hepatitis B virus infection and liver metastasis in colorectal cancer.
- Author
-
Le, Chenqin, Liu, Chengcheng, Lu, Bin, Zhou, Xinbin, Jiamaliding, Yeernaer, Jin, Tian, Dai, Siqi, Li, Jun, Ding, Kefeng, and Xiao, Qian
- Subjects
COLORECTAL liver metastasis ,PROPENSITY score matching ,HEPATITIS B virus ,LIVER metastasis ,COLORECTAL cancer - Abstract
The association between Hepatitis B virus (HBV) infection and colorectal liver metastases (CRLM) remains ambiguous in current population‐based evidence. To clarify this, we present a retrospective analysis of 5871 colorectal cancer (CRC) patients. Propensity score matching (PSM) was applied to harmonize age and sex disparities within HBV+ (n = 1696) and HBV‐ (n = 4175) groups and further within HBV+ subgroups of chronic (CHB, n = 474) and occult (OHB, n = 1222) infections. Our initial results indicated a significant association between HBV infection and synchronous colorectal liver metastasis (SYN‐CRLM); however, this association dissipated after PSM was employed to adjust for confounding variables. No significant association was observed between HBV infection and metachronous colorectal liver metastases (MET‐CRLM) both before and after PSM. Further analysis revealed that HBV replication status did not influence the incidence of CRLM. However, HBV+ participants demonstrated an increased incidence of metachronous extrahepatic metastases, particularly to the lungs. Our findings imply that neither past nor present HBV infection is significantly correlated with the occurrence of SYN‐CRLM or MET‐CRLM. The absence of an association between HBV replication status and CRLM incidence highlights the importance of incorporating a broader range of factors in the clinical management of CRLM beyond the status of HBV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. New trends in surgery for colorectal liver metastasis.
- Author
-
Kron, Philipp and Lodge, Peter
- Subjects
COLORECTAL liver metastasis ,LIVER surgery ,PROCTOLOGY ,MEDICAL personnel - Abstract
By presenting the most up‐to‐date findings and incorporating the latest evidence, this article seeks to present a comprehensive guide for navigating the complexities inherent in the management of colorectal liver metastasis. It aims to serve as a valuable resource offering clinicians and healthcare professionals an understanding of the diverse modalities and approaches available for treating this challenging and multifaceted disease. In an era of rapidly evolving medical knowledge, this article examines the latest insights to make informed decisions in the realm of colorectal liver metastasis management. The article does not only highlight the up‐to‐date knowledge but also provides the evidence for existing therapeutic strategies. This practical tool provides evidence‐based recommendations to clinicians, thereby contributing to the ongoing advancement of effective treatment strategies for this challenging disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Stage IV Rectal Cancer and Timing of Surgical Approach.
- Author
-
Panni, Roheena Z. and D'Angelica, Michael
- Abstract
Liver metastases are seen in at least 60% of patients with colorectal cancer at some point during the course of their disease. The management of both primary and liver disease is uniquely challenging in rectal cancer due to competing treatments and complex sequence of treatments depending on the clinical presentation of disease. Recently, several novel concepts are shaping new treatment paradigms, including changes in timing, sequence, and duration of therapies combined with potential deescalation of treatment components. Overall, the treatment of this clinical scenario mandates multidisciplinary evaluation and personalization of care; however, there is still considerable debate regarding the timing of liver metastasectomy in the context of the overall treatment plan. Herein, we will discuss the current literature on management of rectal cancer with synchronous liver metastasis, current treatment approaches with respect to chemotherapy, and role of hepatic artery infusion therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Machine learning-based screening and validation of liver metastasis-specific genes in colorectal cancer
- Author
-
Shiyao Zheng, Hongxin He, Jianfeng Zheng, Xingshu Zhu, Nan Lin, Qing Wu, Enhao Wei, Caiming Weng, Shuqian Chen, Xinxiang Huang, Chenxing Jian, Shen Guan, and Chunkang Yang
- Subjects
Machine learning ,Colorectal liver metastasis ,Bioinformatics ,Tumor immune microenvironment ,Prognosis ,Medicine ,Science - Abstract
Abstract Colorectal liver metastasis (CRLM) is challenging in the clinical treatment of colorectal cancer. Limited research has been conducted on how CRLM develops. RNA sequencing data were obtained from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). Four machine learning algorithms were used to screen the hub CRLM-specific genes, including Least Absolute Shrinkage and Selection Operator (Lasso), Random forest, SVM-RFE, and XGboost. The model for identifying CRLM was developed using stepwise logistic regression and was validated using internal and independent datasets. The prognostic value of hub CRLM-specific genes was assessed using the Lasso-Cox method. The in vitro experiments were performed using SW620 cells. The CRLM identification model was developed based on four CRLM-specific genes (SPP1, ZG16, P2RY14, and PRKAR2B), and the model efficacy was validated using GSE41258 and three external cohorts. Five CRLM-specific prognostic hub genes, SPP1, ZG16, P2RY14, CYP2E1, and C5, were identified using the Lasso-Cox algorithm, and a risk score was constructed. The risk score was validated using the GSE39582 cohort. Three genes have both efficacy in identifying CRLM and prognostic value: ZG16, P2RY14, and SPP1. Immune infiltration and enrichment analyses demonstrated that SPP1 was associated with M2 macrophage polarization and extracellular matrix remodeling. In vitro experiments indicated that SPP1 may act as a cancer-promoting factor. The hub CRLM-specific gene SPP1 can help determine the diagnosis, prognosis, and immune infiltration of patients with CRLM.
- Published
- 2024
- Full Text
- View/download PDF
28. Robotic-Assisted One-Stage Resection of Colorectal Cancer with Liver Metastases
- Author
-
Ceccarelli, Graziano, Rocca, Aldo, Patriti, Alberto, Bugiantella, Walter, Ermili, Fabio, Coratti, Andrea, De Rosa, Michele, Ceccarelli, Graziano, editor, and Coratti, Andrea, editor
- Published
- 2024
- Full Text
- View/download PDF
29. Postoperative Exercise Training in Patients With Colorectal Liver Metastases Undergoing Surgery (ELMA) (ELMA)
- Author
-
Jesper Frank Christensen, PhD, Principal investigator
- Published
- 2023
30. Cholestasis-induced phenotypic transformation of neutrophils contributes to immune escape of colorectal cancer liver metastasis.
- Author
-
Sun, Li, Yang, Nanyan, Liu, Zhihong, Ye, Xiandong, Cheng, Mengting, Deng, Lingjun, Zhang, Junhao, Wu, Jingjing, Shi, Min, and Liao, Wangjun
- Subjects
- *
COLORECTAL liver metastasis , *PHENOTYPIC plasticity , *LIQUID chromatography-mass spectrometry , *NEUTROPHILS , *IMMUNOTHERAPY , *LIVER metastasis , *LIPOCALINS , *LIVER histology - Abstract
Background: Cholestasis is a common yet severe complication that occurs during the advancement of liver metastasis. However, how cholestasis impacts the development, treatment, and tumor microenvironment (TME) of liver metastasis remains to be elucidated. Methods: Extrahepatic and intrahepatic cholestatic mouse models with liver metastasis were established to detect the differential expression levels of genes, infiltration of immune cells and change in bile acid-associated metabolites by using RNA-Sequencing, flowcytometry, and liquid chromatography and mass spectrometry. Western blot was applied to neutrophils under the stimulation of primary bile acids (BAs) in vitro to study the mechanism of phenotypic alteration. In vitro coculture of BA-treated neutrophils with CD8+ T cells were performed to study the immune-suppressive effect of phenotypic-altered neutrophils. Clinical samples collected from colorectal cancer patients with liver metastasis and cholestasis were applied to RNA-Seq. Results: Compared to non-cholestatic mice, the progression of liver metastasis of cholestatic mice was significantly accelerated, which was associated with increased neutrophil infiltration and T-cell exclusion. Both neutrophils and T cells expressed higher immunosuppressive markers in the cholestatic mouse model, further indicating that an immunosuppressive tumor microenvironment was induced during cholestasis. Although neutrophils deletion via anti-Ly6G antibody partially hindered liver metastasis progression, it reduced the overall survival of mice. Tauro-β-muricholic acid (Tβ-MCA) and Glycocholic acid (GCA), the two most abundant cholestasis-associated primary BAs, remarkably promoted the expression of Arg1 and iNOS on neutrophils via p38 MAPK signaling pathway. In addition, BAs-pretreated neutrophils significantly suppressed the activation and cytotoxic effects of CD8+ T cells, indicating that the immunosuppressive phenotype of neutrophils was directly induced by BAs. Importantly, targeting BA anabolism with Obeticholic acid (OCA) under cholestasis effectively suppressed liver metastasis progression, enhanced the efficacy of immune checkpoint blockade, and prolonged survival of mice. Conclusions: Our study reveals the TME of cholestasis-associated liver metastasis and proposes a new strategy for such patients by targeting bile acid anabolism. Schematic model depicting the proposed mechanism of cholestasis-mediated progression of colorectal liver metastasis. As cholestasis progresses, excessive primary bile acids that accumulate in the liver intoxicates hepatocytes, which lead to exacerbated release of chemokines, particularly CXCL2 and CXCL5. Neutrophils are then accumulated by CXCL2 and CXCL5 and undergo an immunosuppressive-phenotypic alteration induced by direct stimulation of BAs via activating the p38 MAPK signaling pathway, which eventually led to the dysfunction of T cells and progression of LM. Targeting bile acid anabolism can effectively restore the immune-activated microenvironment and prevent the progression of LM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Tuning Tumor Targeting and Ratiometric Photoacoustic Imaging by Fine‐Tuning Torsion Angle for Colorectal Liver Metastasis Diagnosis.
- Author
-
Xu, Jinyuan, Lv, Zhangkang, Wang, Liping, Wu, Xingqing, Tan, Bisui, Shen, Xing‐Can, and Chen, Hua
- Subjects
- *
COLORECTAL liver metastasis , *ACOUSTIC imaging , *LIVER metastasis , *DIHEDRAL angles , *LIVER cancer - Abstract
Photoacoustic (PA) tomography is an emerging biomedical imaging technology for precision cancer medicine. Conventional small‐molecule PA probes usually exhibit a single PA signal and poor tumor targeting that lack the imaging reliability. Here, we introduce a series of cyanine/hemicyanine interconversion dyes (denoted
Cy‐HCy) for PA/fluorescent dual‐mode probe development that features optimized ratiometric PA imaging and tunable tumor‐targeting ability for precise diagnosis and resection of colorectal cancer (CRC). Importantly,Cy‐HCy can be presented in cyanine (inherent tumor targeting and long NIR PA wavelength) and hemicyanine (poor tumor targeting and short NIR PA wavelength) by fine‐tuning torsion angle and the ingenious transformation between cyanine and hemicyanine through regulation optically tunable group endows the NIR ratiometric PA and tunable tumor‐targeting properties. To demonstrate the applicability ofCy‐HCy dyes, we designed the first small‐molecule tumor‐targeting and NIR ratiometric PA probeCy‐HCy‐H2S for precise CRC liver metastasis diagnosis, activated by H2S (a CRC biomarker). Using this probe, we not only visualized the subcutaneous tumor and liver metastatic cancers in CRC mouse models but also realized PA and fluorescence image‐guided tumor excision. We expect thatCy‐HCy will be generalized for creating a wide variety of inherently tumor‐targeting NIR ratiometric PA probes in oncological research and practice. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
32. Partial hepatectomy accelerates colorectal metastasis by priming an inflammatory premetastatic niche in the liver.
- Author
-
Luenstedt, Jost, Hoping, Fabian, Feuerstein, Reinhild, Mauerer, Bernhard, Berlin, Christopher, Rapp, Julian, Marx, Lisa, Reichardt, Wilfried, Elverfeldt, Dominik von, Ruess, Dietrich Alexander, Plundrich, Dorothea, Laessle, Claudia, Jud, Andreas, Neeff, Hannes Philipp, Holzner, Philipp Anton, Fichtner-Feigl, Stefan, and Kesselring, Rebecca
- Subjects
COLORECTAL liver metastasis ,LIVER metastasis ,METASTASIS ,HEPATECTOMY ,CANCER invasiveness - Abstract
Background: Resection of colorectal liver metastasis is the standard of care for patients with Stage IV CRC. Despite undoubtedly improving the overall survival of patients, pHx for colorectal liver metastasis frequently leads to disease recurrence. The contribution of this procedure to metastatic colorectal cancer at a molecular level is poorly understood. We designed a mouse model of orthograde metastatic colorectal cancer (CRC) to investigate the effect of partial hepatectomy (pHx) on tumor progression. Methods: CRC organoids were implanted into the cecal walls of wild type mice, and animals were screened for liver metastasis. At the time of metastasis, 1/3 partial hepatectomy was performed and the tumor burden was assessed longitudinally using MRI. After euthanasia, different tissues were analyzed for immunological and transcriptional changes using FACS, qPCR, RNA sequencing, and immunohistochemistry. Results: Mice that underwent pHx presented significant liver hypertrophy and an increased overall metastatic load compared with SHAM operated mice in MRI. Elevation in the metastatic volume was defined by an increase in de novo liver metastasis without any effect on the growth of each metastasis. Concordantly, the livers of pHx mice were characterized by neutrophil and bacterial infiltration, inflammatory response, extracellular remodeling, and an increased abundance of tight junctions, resulting in the formation of a premetastatic niche, thus facilitating metastatic seeding. Conclusions: Regenerative pathways following pHx accelerate colorectal metastasis to the liver by priming a premetastatic niche. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Simulated deep CT characterization of liver metastases with high-resolution filtered back projection reconstruction.
- Author
-
Wiedeman, Christopher, Lorraine, Peter, Wang, Ge, Do, Richard, Simpson, Amber, Peoples, Jacob, and De Man, Bruno
- Subjects
ARTIFICIAL neural networks ,REAR-screen projection ,ARTIFICIAL intelligence ,COMPUTED tomography ,COLORECTAL liver metastasis - Abstract
Early diagnosis and accurate prognosis of colorectal cancer is critical for determining optimal treatment plans and maximizing patient outcomes, especially as the disease progresses into liver metastases. Computed tomography (CT) is a frontline tool for this task; however, the preservation of predictive radiomic features is highly dependent on the scanning protocol and reconstruction algorithm. We hypothesized that image reconstruction with a high-frequency kernel could result in a better characterization of liver metastases features via deep neural networks. This kernel produces images that appear noisier but preserve more sinogram information. A simulation pipeline was developed to study the effects of imaging parameters on the ability to characterize the features of liver metastases. This pipeline utilizes a fractal approach to generate a diverse population of shapes representing virtual metastases, and then it superimposes them on a realistic CT liver region to perform a virtual CT scan using CatSim. Datasets of 10,000 liver metastases were generated, scanned, and reconstructed using either standard or high-frequency kernels. These data were used to train and validate deep neural networks to recover crafted metastases characteristics, such as internal heterogeneity, edge sharpness, and edge fractal dimension. In the absence of noise, models scored, on average, 12.2% ( α = 0.012 ) and 7.5% ( α = 0.049) lower squared error for characterizing edge sharpness and fractal dimension, respectively, when using high-frequency reconstructions compared to standard. However, the differences in performance were statistically insignificant when a typical level of CT noise was simulated in the clinical scan. Our results suggest that high-frequency reconstruction kernels can better preserve information for downstream artificial intelligence-based radiomic characterization, provided that noise is limited. Future work should investigate the information-preserving kernels in datasets with clinical labels. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001).
- Author
-
Ozawa, Mayumi, Watanabe, Jun, Ishibe, Atsushi, Goto, Koki, Fujii, Yoshiro, Nakagawa, Kazuya, Suwa, Yusuke, Suwa, Hirokazu, Masui, Hidenobu, Sugita, Mitsutaka, Mochizuki, Yasuhisa, Yamagishi, Shigeru, Hasegawa, Seiji, Homma, Yuki, Momiyama, Masashi, Kumamoto, Takafumi, Matsuyama, Ryusei, Takeda, Kazuhisa, Taguri, Masataka, and Endo, Itaru
- Subjects
- *
COLORECTAL liver metastasis , *PACLITAXEL , *HEPATECTOMY , *OXALIPLATIN , *ADJUVANT chemotherapy , *CARBOPLATIN - Abstract
Purpose: The high recurrence rate of colorectal cancer liver metastasis (CRCLM) after surgery remains a crucial problem. However, adjuvant chemotherapy after hepatectomy for CRCLM has not yet been established. This study evaluated the efficacy of adjuvant therapy with S-1 and oxaliplatin (SOX). Methods: In a multicenter, randomized, phase II study, patients undergoing curative resection of CRCLM were randomly enrolled in a 1:1 ratio to either the low- or high-dose group. S-1 and oxaliplatin were administered from days 1 to 14 of a 3-week cycle as a 2-h infusion every 3 weeks. The dose of S-1 was fixed at 80 mg/m2. The doses in the low- and high-dose oxaliplatin groups were 100 mg/m2 (low-dose group) and 130 mg/m2 (high-dose group), respectively. This treatment was repeated eight times. The primary endpoint was the rate of discontinuation owing to toxicity. The secondary endpoints were the relapse-free survival (RFS) and frequency of adverse events (AEs). Results: Between August 2010 and March 2015, 44 patients (low-dose group: 31 patients and high-dose group: 13 patients) were enrolled in the study. Of these, one patient was excluded from the efficacy analysis. In the high-dose group, five of nine patients were unable to continue the study due to toxicity in February 2013. At that time, recruitment to the high-dose group was stopped from the protocol. The relative dose intensity (RDI) for S-1 in the low- and high-dose groups were 49.8 and 48.7% (p = 0.712), and that for oxaliplatin was 75.9 and 73.0% (p = 0.528), respectively. The rates of discontinuation due to toxicity were 60 and 53.8% in the low- and high-dose groups, respectively, with no marked difference noted between the groups (p = 0.747). The frequency of grade ≥ 3 common adverse events was neutropenia (23.3%/23.1%), diarrhea (13.3%/15.4%), and peripheral sensory neuropathy (6.7%/7.7%). The disease-free survival (DFS) at 3 years was 52.9% in the low-dose group, which was not significantly different from that in the high-dose group (46.2%; p = 0.705). Conclusions: SOX regimens as adjuvant therapy after hepatectomy for CRCLM had high rates of discontinuation due to toxicity in both groups. In particular, the RDI of S-1 was < 50%. Therefore, the SOX regimen is not recommended as adjuvant chemotherapy after hepatectomy for CRCLM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Short-term outcomes of laparoscopic extended hepatectomy versus major hepatectomy: a single-center experience.
- Author
-
Costa, Adriano C., Mazzotta, Alessandro, Santa-Cruz, Fernando, Coelho, Fabricio F., Tribillon, Ecoline, Gayet, Brice, Herman, Paulo, and Soubrane, Olivier
- Subjects
- *
LIVER surgery , *RIGHT hemicolectomy , *HEPATECTOMY , *COLORECTAL liver metastasis , *LAPAROSCOPIC surgery , *BLOOD transfusion , *LIVER failure - Abstract
Laparoscopic major hepatectomy (LMH) remains restricted to a few specialized centers and poses a challenge to surgeons performing laparoscopic resections. Laparoscopic extended resections are even more complex and rarely conducted. From a single-institution database, we compared the short-term outcomes of patients who underwent major and extended laparoscopic resections, stratifying the entire retrospective cohort into four groups: right hepatectomy, left hepatectomy, right extended hepatectomy, and left extended hepatectomy. Patient demographics, tumor characteristics, operative variables, and especially postoperative outcomes were evaluated. 250 patients underwent major and extended laparoscopic liver resections, including 160 right, 31 right extended, 36 left, and 23 left extended laparoscopic hepatectomies. The most common indication for resection was colorectal liver metastases (64%). Laparoscopic extended hepatectomy (LEH) showed significantly longer operative time, more blood loss, need for Pringle maneuver, conversion to open surgery, higher rates of liver failure, postoperative ascites, and intra-abdominal hemorrhage, R1 margins and length of stay when compared with the LMH group. Mortality rates were similar between groups. Multivariate analysis revealed intraoperative blood transfusion (OR = 5.1[CI-95%: 1.15–6.79]; p = 0.02) as an independent predictor for major complications. LEH showed to be feasible, however with higher blood loss and significantly associated to major complications. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Hospital variation and outcomes after repeat hepatic resection for colorectal liver metastases: a nationwide cohort study.
- Author
-
de Graaff, Michelle R., Klaase, Joost M., den Dulk, Marcel, te Riele, Wouter W., Hagendoorn, Jeroen, van Heek, N. Tjarda, Vermaas, M., Belt, Eric J. Th., Bosscha, Koop, Slooter, Gerrit D., Leclercq, Wouter K.G., Liem, Mike S.L., Mieog, J. Sven D., Swijnenburg, Rutger-Jan, van Dam, Ronald M., Verhoef, Cees, Kuhlmann, Koert, van Duijvendijk, Peter, Gerhards, Michael F., and Gobardhan, Paul
- Subjects
- *
LIVER surgery , *COLORECTAL liver metastasis , *COHORT analysis , *OVERALL survival , *HOSPITALS , *DATABASES - Abstract
Approximately 70% of patients with colorectal liver metastases (CRLM) experiences intrahepatic recurrence after initial liver resection. This study assessed outcomes and hospital variation in repeat liver resections (R-LR). This population-based study included all patients who underwent liver resection for CRLM between 2014 and 2022 in the Netherlands. Overall survival (OS) was collected for patients operated on between 2014 and 2018 by linkage to the insurance database. Data of 7479 liver resections (1391 (18.6%) repeat and 6088 (81.4%) primary) were analysed. Major morbidity and mortality were not different. Factors associated with major morbidity included ASA 3+, major liver resection, extrahepatic disease, and open surgery. Five-year OS after repeat versus primary liver resection was 42.3% versus 44.8%, P = 0.37. Factors associated with worse OS included largest CRLM >5 cm (aHR 1.58, 95% CI: 1.07–2.34, P = 0.023), >3 CRLM (aHR 1.33, 95% CI: 1.00–1.75, P = 0.046), extrahepatic disease (aHR 1.60, 95% CI: 1.25–2.04, P = 0.001), positive tumour margins (aHR 1.42, 95% CI: 1.09–1.85, P = 0.009). Significant hospital variation in performance of R-LR was observed, median 18.9% (8.2% to 33.3%). Significant hospital variation was observed in performance of R-LR in the Netherlands reflecting different treatment decisions upon recurrence. On a population-based level R-LR leads to satisfactory survival. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Independent validation of CT radiomics models in colorectal liver metastases: predicting local tumour progression after ablation.
- Author
-
van der Reijd, Denise J., Guerendel, Corentin, Staal, Femke C. R., Busard, Milou P., De Oliveira Taveira, Mateus, Klompenhouwer, Elisabeth G., Kuhlmann, Koert F. D., Moelker, Adriaan, Verhoef, Cornelis, Starmans, Martijn P. A., Lambregts, Doenja M. J., Beets-Tan, Regina G. H., Benson, Sean, and Maas, Monique
- Subjects
- *
COLORECTAL liver metastasis , *RADIOMICS , *FEATURE extraction , *CANCER invasiveness , *TUMORS - Abstract
Objectives: Independent internal and external validation of three previously published CT-based radiomics models to predict local tumor progression (LTP) after thermal ablation of colorectal liver metastases (CRLM). Materials and methods: Patients with CRLM treated with thermal ablation were collected from two institutions to collect a new independent internal and external validation cohort. Ablation zones (AZ) were delineated on portal venous phase CT 2–8 weeks post-ablation. Radiomics features were extracted from the AZ and a 10 mm peri-ablational rim (PAR) of liver parenchyma around the AZ. Three previously published prediction models (clinical, radiomics, combined) were tested without retraining. LTP was defined as new tumor foci appearing next to the AZ up to 24 months post-ablation. Results: The internal cohort included 39 patients with 68 CRLM and the external cohort 52 patients with 78 CRLM. 34/146 CRLM developed LTP after a median follow-up of 24 months (range 5–139). The median time to LTP was 8 months (range 2–22). The combined clinical-radiomics model yielded a c-statistic of 0.47 (95%CI 0.30–0.64) in the internal cohort and 0.50 (95%CI 0.38–0.62) in the external cohort, compared to 0.78 (95%CI 0.65–0.87) in the previously published original cohort. The radiomics model yielded c-statistics of 0.46 (95%CI 0.29–0.63) and 0.39 (95%CI 0.28–0.52), and the clinical model 0.51 (95%CI 0.34–0.68) and 0.51 (95%CI 0.39–0.63) in the internal and external cohort, respectively. Conclusion: The previously published results for prediction of LTP after thermal ablation of CRLM using clinical and radiomics models were not reproducible in independent internal and external validation. Clinical relevance statement: Local tumour progression after thermal ablation of CRLM cannot yet be predicted with the use of CT radiomics of the ablation zone and peri-ablational rim. These results underline the importance of validation of radiomics results to test for reproducibility in independent cohorts. Key Points: • Previous research suggests CT radiomics models have the potential to predict local tumour progression after thermal ablation in colorectal liver metastases, but independent validation is lacking. • In internal and external validation, the previously published models were not able to predict local tumour progression after ablation. • Radiomics prediction models should be investigated in independent validation cohorts to check for reproducibility. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Inhibition of the Renin-Angiotensin System Improves Response to Neoadjuvant Therapy in Patients With Liver Metastasis of Colorectal Cancers.
- Author
-
Wirsik, Naita M., Appel, Pia C., Braun, Alexander, Strowitzki, Moritz J., Schleussner, Nikolai, Nienhüser, Henrik, Schneider, Martin, and Schmidt, Thomas
- Subjects
- *
COLORECTAL liver metastasis , *NEOADJUVANT chemotherapy , *PICTURE archiving & communication systems , *RENIN-angiotensin system , *ANTIHYPERTENSIVE agents , *LIVER metastasis - Abstract
Renin-angiotensin-aldosterone system inhibitors (RAAS-I) have been shown to prolong overall survival in patients with liver metastasized colorectal cancer in combination with antiangiogenic treatment. The effects of RAAS-I combined with neoadjuvant chemotherapy on colorectal cancer liver metastasis remain unexplored. We aimed to study the response of patients undergoing liver resection to RAAS-I in combination with neoadjuvant therapy to elucidate their potential benefits. Between February 2005 and May 2012, 62 patients fulfilled the inclusion criteria for distant metastasis (cM1) and comparable computed tomography or magnetic resonance tomography scans in the Picture Archiving Communication System of our center before and after neoadjuvant chemotherapy. Follow-up data and clinicopathological characteristics were collected from a prospective database and retrospectively investigated. The chemotherapeutic response to liver metastasis was evaluated according to the Response Evaluation Criteria in Solid Tumors criteria 1.1. Comparing the average reduction of measured lesions, a significant response to chemotherapy was detected in the patients receiving RAAS-I (n = 24) compared to those who did not (n = 38) (P = 0.031). Interestingly, the effect was more distinctive when the size reduction was compared between high responses with more than 50% size reduction of all measured lesions (P = 0.011). In the subgroup analysis of patients receiving bevacizumab treatment, high responses to chemotherapy were observed only in the RAAS-I cohort (28.6% versus 0%, P = 0.022). For neoadjuvantly treated patients, concomitant antihypertensive treatment with RAAS-I showed a higher total size reduction of liver metastasis as a sign of treatment response, especially in combination with antiangiogenic treatment with bevacizumab. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. A Comprehensive Prognostic Model for Colon Adenocarcinoma Depending on Nuclear-Mitochondrial-Related Genes.
- Author
-
Lv, Lingling, Huang, Yuqing, Li, Qiong, Wu, Yuan, and Zheng, Lan
- Subjects
PROGNOSTIC models ,COLORECTAL liver metastasis ,REACTIVE oxygen species ,DISEASE risk factors ,COLON (Anatomy) - Abstract
Background: Colon adenocarcinoma (COAD) has increasing incidence and is one of the most common malignant tumors. The mitochondria involved in cell energy metabolism, oxygen free radical generation, and cell apoptosis play important roles in tumorigenesis and progression. The relationship between mitochondrial genes and COAD remains largely unknown. Methods: COAD data including 512 samples were set out from the UCSC Xena database. The nuclear mitochondrial-related genes (NMRGs)-related risk prognostic model and prognostic nomogram were constructed, and NMRGs-related gene mutation and the immune environment were analyzed using bioinformatics methods. Then, a liver metastasis model of colorectal cancer was constructed and protein expression was detected using Western blot assay. Results: A prognostic model for COAD was constructed. Comparing the prognostic model dataset and the validation dataset showed considerable correlation in both risk grouping and prognosis. Based on the risk score (RS) model, the samples of the prognostic dataset were divided into high risk group and low risk group. Moreover, pathologic N and T stage and tumor recurrence in the two risk groups were significantly different. The four prognostic factors, including age and pathologic T stage in the nomogram survival model also showed excellent predictive performance. An optimal combination of nine differentially expressed NMRGs was finally obtained, including LARS2, PARS2, ETHE1, LRPPRC, TMEM70, AARS2, ACAD9, VARS2, and ATP8A2. The high-RS group had more inflamed immune features, including T and CD4
+ memory cell activation. Besides, mitochondria-associated LRPPRC and LARS2 expression levels were increased in vivo xenograft construction and liver metastases assays. Conclusion: This study established a comprehensive prognostic model for COAD, incorporating nine genes associated with nuclear-mitochondrial functions. This model demonstrates superior predictive performance across four prognostic factors: age, pathological T stage, tumor recurrence, and overall prognosis. It is anticipated to be an effective model for enhancing the prognosis and treatment of COAD. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
40. Risk of tumour seeding in patients with liver lesions undergoing biopsy with or without concurrent ablation: meta-analysis.
- Author
-
Maducolil, Jeremy E, Girgis, Stephanie, Mustafa, Mohammad A, Gittens, Jayden, Fok, Matthew, Mahapatra, Sunanda, Vimalachandran, Dale, and Jones, Robert
- Subjects
BIOPSY ,COLORECTAL liver metastasis ,LIVER - Abstract
This article is a meta-analysis that examines the risk of tumor seeding in patients with liver lesions undergoing biopsy with or without concurrent ablation. The study found that the overall risk of needle tract seeding during liver biopsies was as low as 1%. The analysis included 23 studies representing 8,857 patients, and the majority of the studies were retrospective. The results suggest that the risk of seeding associated with liver biopsies may be lower than previously thought, which could inform clinicians and patients when considering the procedure. However, the study acknowledges limitations, such as the small sample size of patients undergoing biopsy with concurrent ablation and the lack of a standardized definition for needle tract seeding. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
41. Importance of resection margin after resection of colorectal liver metastases in the era of modern chemotherapy: population-based cohort study.
- Author
-
Östrand, Emil, Rystedt, Jenny, Engstrand, Jennie, Frühling, Petter, Hemmingsson, Oskar, Sandström, Per, Eilard, Malin Sternby, Tingstedt, Bobby, and Buchwald, Pamela
- Subjects
LIVER surgery ,COLORECTAL liver metastasis ,SURGICAL margin ,CHOLANGIOCARCINOMA ,PROPORTIONAL hazards models ,OVERALL survival - Abstract
Background Resection margin has been associated with overall survival following liver resection for colorectal liver metastasis. The aim of this study was to examine how resection margins of 0.0 mm, 0.1–0.9 mm and ≥1 mm influence overall survival in patients resected for colorectal liver metastasis in a time of modern perioperative chemotherapy and surgery. Methods Using data from the national registries Swedish Colorectal Cancer Registry and Swedish National Quality Registry for Liver, Bile Duct and Gallbladder Cancer, patients that had liver resections for colorectal liver metastasis between 2009 and 2013 were included. In patients with a narrow or unknown surgical margin the original pathological reports were re-reviewed. Factors influencing overall survival were analysed using a Cox proportional hazard model. Results A total of 754 patients had a known margin status, of which 133 (17.6%) patients had a resection margin <1 mm. The overall survival in patients with a margin of 0 mm or 0.1–0.9 mm was 42 (95% c.i. 31 to 53) and 48 (95% c.i. 35 to 62) months respectively, compared with 75 (95% c.i. 65 to 85) for patients with ≥1 mm margin, P < 0.001. Margins of 0 mm or 0.1–0.9 mm were associated with poor overall survival in the multivariable analysis, HR 1.413 (95% c.i. 1.030 to 1.939), P = 0.032, and 1.399 (95% c.i. 1.025 to 1.910), P = 0.034, respectively. Conclusions Despite modern chemotherapy the resection margin is still an important factor for the survival of patients resected for colorectal liver metastasis, and a margin of ≥1 mm is needed to achieve the best possible outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. IFNγ at the early stage induced after cryo-thermal therapy maintains CD4+ Th1-prone differentiation, leading to long-term antitumor immunity.
- Author
-
Junjun Wang, Yue Lou, Shicheng Wang, Zelu Zhang, Jiaqi You, Yongxin Zhu, Yichen Yao, Yuankai Hao, Ping Liu, and Xu, Lisa X.
- Subjects
MYELOID-derived suppressor cells ,COLORECTAL liver metastasis ,TH1 cells ,REGULATORY T cells ,IMMUNITY - Abstract
Introduction: Recently, more and more research illustrated the importance of inducing CD4
+ T helper type (Th)-1 dominant immunity for the success of tumor immunotherapy. Our prior studies revealed the crucial role of CD4+ Th1 cells in orchestrating systemic and durable antitumor immunity, which contributes to the satisfactory outcomes of the novel cryo-thermal therapy in the B16F10 tumor model. However, the mechanism for maintaining the cryo-thermal therapymediated durable CD4+ Th1-dominant response remains uncovered. Additionally, cryo-thermal-induced early-stage CD4+ Th1-dominant T cell response showed a correlation with the favorable prognosis in patients with colorectal cancer liver metastasis (CRCLM). We hypothesized that CD4+ Th1- dominant differentiation induced during the early stage post cryo-thermal therapy would affect the balance of CD4+ subsets at the late phase. Methods: To understand the role of interferon (IFN)-γ, the major effector of Th1 subsets, in maintaining long-term CD4+ Th1-prone polarization, B16F10 melanoma model was established in this study and a monoclonal antibody was used at the early stage post cryo-thermal therapy for interferon (IFN)-γ signaling blockade, and the influence on the phenotypic and functional change of immune cells was evaluated. Results: IFNγ at the early stage after cryo-thermal therapy maintained longlasting CD4+ Th1-prone immunity by directly controlling Th17, Tfh, and Tregs polarization, leading to the hyperactivation of Myeloid-derived suppressor cells (MDSCs) represented by abundant interleukin (IL)-1β generation, and thereby further amplifying Th1 response. Discussion: Our finding emphasized the key role of early-phase IFNγ abundance post cryo-thermal therapy, which could be a biomarker for better prognosis after cryo-thermal therapy. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
43. Establishment of a neutrophil extracellular trap-related prognostic signature for colorectal cancer liver metastasis and expression validation of CYP4F3.
- Author
-
Tang, Xiao-Li, Xu, Zi-Yang, Guan, Jiao, Yao, Jing, Tang, Xiao-Long, Zhou, Zun-Qiang, and Zhang, Zheng-Yun
- Subjects
- *
COLORECTAL liver metastasis , *NEUTROPHILS , *LIVER metastasis , *RANDOM operators , *GENE expression profiling - Abstract
Liver metastasis stands as the primary contributor to mortality among patients diagnosed with colorectal cancer (CRC). Neutrophil extracellular traps (NETs) emerge as pivotal players in the progression and metastasis of cancer, showcasing promise as prognostic biomarkers. Our objective is to formulate a predictive model grounded in genes associated with neutrophil extracellular traps and identify novel therapeutic targets for combating CRLM. We sourced gene expression profiles from the Gene Expression Omnibus (GEO) database. Neutrophil extracellular trap-related gene set was obtained from relevant literature and cross-referenced with the GEO datasets. Differentially expressed genes (DEGs) were identified through screening via the least absolute shrinkage and selection operator regression and random forest modeling, leading to the establishment of a nomogram and subtype analysis. Subsequently, a thorough analysis of the characteristic gene CYP4F3 was undertaken, and our findings were corroborated through immunohistochemical staining. We identified seven DEGs (ATG7, CTSG, CYP4F3, F3, IL1B, PDE4B, and TNF) and established nomograms for the occurrence and prognosis of CRLM. CYP4F3 is highly expressed in CRC and colorectal liver metastasis (CRLM), exhibiting a negative correlation with CRLM prognosis. It may serve as a potential therapeutic target for CRLM. A novel prognostic signature related to NETs has been developed, with CYP4F3 identified as a risk factor and potential target for CRLM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Surgical Resection in Colorectal Liver Metastasis: An Umbrella Review.
- Author
-
Milazzo, Martina, Todeschini, Letizia, Caimano, Miriam, Mattia, Amelia, Cristin, Luca, Martinino, Alessandro, Bianco, Giuseppe, Spoletini, Gabriele, and Giovinazzo, Francesco
- Subjects
- *
LIVER tumors , *PATIENT selection , *COLORECTAL cancer , *TREATMENT effectiveness , *METASTASIS , *SYSTEMATIC reviews , *MEDLINE , *DISEASES , *MEDICAL databases , *QUALITY assurance , *PROGRESSION-free survival , *OVERALL survival - Abstract
Simple Summary: Colorectal cancer is a leading cause of death worldwide, with a significant number of patients presenting with liver metastases at diagnosis. The best treatment currently involves the surgical removal of these metastases, yet the optimal timing and method for this surgery are still debated among experts. Our analysis revealed no significant difference in overall survival and disease-free survival between a simultaneous surgery approach and a "bowel-first" approach, while a better 5-year overall survival (5-OS) was found when comparing the former to a "liver-first" approach. However, simultaneous surgeries are associated with a higher risk of perioperative mortality, suggesting that staged surgery might be more beneficial for high-risk patients. This emphasizes the need for personalized treatment plans. Our findings also suggest that anatomic and non-anatomic resections offer similar long-term survival benefits, highlighting the potential for more conservative surgeries to preserve liver function without compromising the effectiveness of cancer treatment. Surgical resection is the gold standard for treating synchronous colorectal liver metastases (CRLM). The resection of the primary tumor and metastatic lesions can follow different sequences: "simultaneous", "bowel-first", and "liver-first". Conservative approaches, such as parenchymal-sparing surgery and segmentectomy, may serve as alternatives to major hepatectomy. A comprehensive search of Medline, Epistemonikos, Scopus, and the Cochrane Library was conducted. Studies evaluating patients who underwent surgery for CRLM and reported survival results were included. Other secondary outcomes were analyzed, including disease-free survival, perioperative complications and mortality, and recurrence rates. Quality assessment was performed using the AMSTAR-2 method. No significant differences in overall survival, disease-free survival, and secondary outcomes were observed when comparing simultaneous to "bowel-first" resections, despite a higher rate of perioperative mortality in the former group. The 5-year OS was significantly higher for simultaneous resection compared to "liver-first" resection. No significant differences in OS and DFS were noted when comparing "liver-first" to "bowel-first" resection, or anatomic to non-anatomic resection. Our umbrella review validates simultaneous surgery as an effective oncological approach for treating SCRLM, though the increased risk of perioperative morbidity highlights the importance of selecting suitable patients. Non-anatomic resections might be favored to preserve liver function and enable future surgical interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
- Author
-
Wang, De-Shen, Ren, Chao, Li, Shan-Shan, Fong, William Pat, Wu, Xiao-Jun, Xiao, Jian, Li, Bin-Kui, Zheng, Yun, Ding, Pei-Rong, Chen, Gong, Qiu, Miao-Zhen, Wang, Zhi-Qiang, Wang, Feng-Hua, Luo, Hui-Yan, Wang, Feng, Wang, Xiao-Zhong, Wang, Ling-Yun, Xie, De-Jin, Chen, Tao, and Li, Li-Ren
- Subjects
- *
COLORECTAL liver metastasis , *ANTINEOPLASTIC combined chemotherapy protocols , *RANDOMIZED controlled trials , *STEREOTACTIC radiotherapy , *CETUXIMAB , *RADIO frequency therapy , *RADIOTHERAPY - Abstract
Background: It remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorectal liver metastases (CRLM). To that end, we sought to comparatively evaluate the efficacy and safety of cetuximab plus FOLFOXIRI (triplet arm) versus cetuximab plus FOLFOX (doublet arm) as a conversion regimen (i.e., unresectable to resectable) in CRC patients with unresectable CRLM. Methods and findings: This open-label, randomized clinical trial was conducted from April 2018 to December 2022 in 7 medical centers across China, enrolling 146 RAS/BRAF wild-type CRC patients with initially unresectable CRLM. A stratified blocked randomization method was utilized to assign patients (1:1) to either the cetuximab plus FOLFOXIRI (n = 72) or cetuximab plus FOLFOX (n = 74) treatment arms. Stratification factors were tumor location (left versus right) and resectability (technically unresectable versus ≥5 metastases). The primary outcome was the objective response rate (ORR). Secondary outcomes included the median depth of tumor response (DpR), early tumor shrinkage (ETS), R0 resection rate, progression-free survival (PFS), overall survival (not mature at the time of analysis), and safety profile. Radiological tumor evaluations were conducted by radiologists blinded to the group allocation. Primary efficacy analyses were conducted based on the intention-to-treat population, while safety analyses were performed on patients who received at least 1 line of chemotherapy. A total of 14 patients (9.6%) were lost to follow-up (9 in the doublet arm and 5 in the triplet arm). The ORR was comparable following adjustment for stratification factors, with 84.7% versus 79.7% in the triplet and doublet arms, respectively (odds ratio [OR] 0.70; 95% confidence intervals [CI] [0.30, 1.67], Chi-square p = 0.42). Moreover, the ETS rate showed no significant difference between the triplet and doublet arms (80.6% (58/72) versus 77.0% (57/74), OR 0.82, 95% CI [0.37, 1.83], Chi-square p = 0.63). Although median DpR was higher in the triplet therapy group (59.6%, interquartile range [IQR], [50.0, 69.7] versus 55.0%, IQR [42.8, 63.8], Mann–Whitney p = 0.039), the R0/R1 resection rate with or without radiofrequency ablation/stereotactic body radiation therapy was comparable with 54.2% (39/72) of patients in the triplet arm versus 52.7% (39/74) in the doublet arm. At a median follow-up of 26.2 months (IQR [12.8, 40.5]), the median PFS was 11.8 months in the triplet arm versus 13.4 months in the doublet arm (hazard ratio [HR] 0.74, 95% CI [0.50, 1.11], Log-rank p = 0.14). Grade ≥ 3 events were reported in 47.2% (35/74) of patients in the doublet arm and 55.9% (38/68) of patients in the triplet arm. The triplet arm was associated with a higher incidence of grade ≥ 3 neutropenia (44.1% versus 27.0%, p = 0.03) and diarrhea (5.9% versus 0%, p = 0.03). The primary limitations of the study encompass the inherent bias in subjective surgical decisions regarding resection feasibility, as well as the lack of a centralized assessment for ORR and resection. Conclusions: The combination of cetuximab with FOLFOXIRI did not significantly improve ORR compared to cetuximab plus FOLFOX. Despite achieving an enhanced DpR, this improvement did not translate into improved R0 resection rates or PFS. Moreover, the triplet arm was associated with an increase in treatment-related toxicity. Trial Registration: ClinicalTrials.gov Identifier: NCT03493048. De-Shen Wang and colleagues evaluate the efficacy and safety of cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as a conversion regimen in CRC patients with initially unresectable colorectal liver metastases. Author summary: Why was this study done?: Liver metastasis is a common and significant challenge in colorectal cancer (CRC). Achieving resection through local treatments such as surgery, radiofrequency treatment, and stereotactic body radiation therapy is crucial for long-term survival. Therefore, identifying strategies to increase the conversion to resection rate in patients with initially unresectable colorectal liver metastases (CRLM) is paramount. Although the combination of an anti-EGFR with a doublet chemotherapy backbone has been established as the upfront conversion regimen in RAS/BRAF wild-type CRC patients with initially unresectable CRLM, several Phase II studies highlighted the substantial efficacy of a triplet chemotherapy backbone. Nevertheless, the added value of an intensified chemotherapy backbone in combination with cetuximab has not been explored in a randomized controlled trial at the time of this study. What did the researchers do and find?: This prospective, open-label, randomized clinical trial aimed to assess the efficacy of upfront cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in a cohort consisting only of RAS/BRAF wild-type CRC patients with initially unresectable CRLM. The study findings reveal that the objective response rates (ORRs) were comparable between the 2 treatment arms. Although a superior depth of tumor response was achieved in the cetuximab plus FOLFOXIRI treatment arm, this did not translate to improved resection rates or progression-free survival (PFS). Instead, this regimen was associated with increased treatment toxicities. What do these findings mean?: Collectively, the TRICE study recommends selecting cetuximab plus FOLFOX as the first-line regimen for RAS/BRAF wild-type CRC patients with unresectable CRLM requiring conversion to resection. Major limitations of the study include the inherent bias in subjective surgical decisions regarding resection feasibility and the lack of centralized assessment for study endpoints. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Drug-eluting beads transcatheter arterial chemoembolization combined with systemic therapy versus systemic therapy alone as first-line treatment for unresectable colorectal liver metastases.
- Author
-
Fuquan Wang, Lei Chen, Chai Bin, Yanyan Cao, Jihua Wang, Guofeng Zhou, and Chuansheng Zheng
- Subjects
COLORECTAL liver metastasis ,CHEMOEMBOLIZATION ,LIVER metastasis ,CANCER chemotherapy ,PROGNOSIS - Abstract
Purpose: The purpose of this retrospective study was to compare the therapeutic efficacy and safety of drug-eluting bead transarterial chemoembolization (DEBTACE) combined with systemic therapy to systemic therapy alone as first-line treatment for unresectable patients with colorectal liver metastases (CRLM). Methods: From December 2017 to December 2022, patients with unresectable CRLM who received systemic therapy with or without DEB-TACE as first-line treatment were included in the study. The primary endpoint was progressionfree survival (PFS). Secondary endpoints were tumor response, conversion rate and adverse events. Results: Ninety-eight patients were enrolled in this study, including 46 patients who received systemic therapy combined with DEB-TACE (DEB-TACE group) and 52 patients who received systemic therapy alone (control group). The median PFS was elevated in the DEB-TACE group compared with the control group (12.1 months vs 8.4 months, p = 0.008). The disease control rate was increased in the DEB-TACE group compared with the control group (87.0% vs 67.3%, p = 0.022). Overall response rates (39.1% vs 25.0%; p = 0.133) and conversion rate to liver resection (33.8% vs 25.0%; p = 0.290) were no different between the two groups. The multivariate analysis showed that treatment options, size of liver metastasis, number of liver metastasis, synchronous metastases, and extrahepatic metastases were independent prognostic factor of PFS. Further subgroup analyses illustrated that PFS was beneficial with the DEB-TACE group in patients with age = 60, male, left colon, synchronous metastases, bilobar, number of liver metastasis > 5, extrahepatic metastases, non-extrahepatic metastases, CEA level < 5 (ng/ml), and KRAS wild-type. No grade 4 or 5 toxicities related to DEB-TACE procedures were observed. Conclusion: In patients with unresectable CRLM, systemic chemotherapy with DEB-TACE as first-line treatment may improve progression-free survival and disease control rate outcomes over systemic chemotherapy alone with manageable safety profile. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. ESGAR 2024 Book of Abstracts.
- Subjects
- *
RECTAL cancer , *PANCREATIC cysts , *POSITRON emission tomography computed tomography , *COLORECTAL liver metastasis , *PICTURE archiving & communication systems , *MACHINE learning , *PROSTATE-specific membrane antigen - Abstract
The Book of Abstracts for the ESGAR 2024 Annual Meeting and Postgraduate Course contains summaries of scientific studies on gastrointestinal and abdominal radiology. The abstracts cover topics such as pancreatic cysts, liver tumors, rectal cancer, and Crohn's disease, among others. The studies explore the use of imaging techniques like MRI, CT, and ultrasound for diagnosing and treating these conditions. The document provides valuable insights into the potential of these imaging methods in improving diagnosis and treatment outcomes. It also includes an index of authors and their scientific sessions, which can be used as a reference for further research. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
48. Exploring the efficacy and safety of drug-eluting beads transarterial chemoembolization in pancreatic cancer liver metastasis.
- Author
-
Ning, Zhouyu, Zhu, Ying, Xie, Lin, Yan, Xia, Hua, Yongqiang, and Meng, Zhiqiang
- Subjects
- *
LIVER cancer , *LIVER metastasis , *CHEMOEMBOLIZATION , *PANCREATIC cancer , *COLORECTAL liver metastasis , *ASPARTATE aminotransferase , *PEPTIDASE - Abstract
Objectives Drug-eluting beads transarterial chemoembolization (DEB-TACE) has shown promise as a treatment modality for primary liver cancer and colorectal cancer liver metastasis. However, its role in pancreatic cancer liver metastasis (PCLM) remains uncertain. This study aimed to investigate the efficacy and safety of DEB-TACE in PCLM patients. Methods A retrospective study included 10 PCLM patients who underwent DEB-TACE using CalliSpheres® microspheres as the chemoembolization material. Treatment response, survival outcomes, adverse events, and liver function indexes were comprehensively assessed. Results Among the patients, complete response, partial response, stable disease, and progressive disease rates were 0.0%, 40.0%, 30.0%, and 30.0%, respectively. The objective response rate was 40.0%, and the disease-control rate was 70.0%. The median progression-free survival (PFS) was 12.0 months (95% CI: 0.0-26.7), with a 1-year PFS rate of 48.0%. The median overall survival (OS) was 18.0 months (95% CI: 6.0-30.0), with a 1-year OS rate of 80.0%. Additionally, no significant differences were observed in any of the liver function indexes, including alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, etc. between pre- and posttreatment evaluations. Adverse events included pain, grade 1-2 vomiting, fever, and transient liver dysfunction. Conclusions DEB-TACE demonstrates a promising treatment response, favorable survival profile, and satisfactory safety in PCLM patients. Advances in knowledge This study adds to the current research by providing novel evidence on the efficacy, safety, and favorable survival outcomes of DEB-TACE in treating PCLM, highlighting its potential as an effective therapeutic option in this specific population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Local recurrence risk factors and outcomes in minimally invasive thermal ablation for liver tumors: a single-institution analysis.
- Author
-
Montalti, Roberto, Cassese, Gianluca, Zidan, Ahmed, Rompianesi, Gianluca, Cesare Giglio, Mariano, Campanile, Silvia, Arena, Lorenza, Maione, Marco, and Troisi, Roberto I.
- Subjects
- *
LIVER tumors , *SURGICAL excision , *REGRESSION analysis , *COLORECTAL liver metastasis , *PREVENTIVE medicine - Abstract
Minimally Invasive thermal ablation (MITA) of liver tumors is a commonly performed procedure, alone or in combination with liver resection. Despite being a first-option strategy for small lesions, it is technically demanding, and many concerns still exist about local disease control. Consecutive patients undergoing MITA from 1-2019 to 12-2022 were retrospectively enrolled. Risk factors of local recurrence were investigated through univariate and multivariable cox regression analysis. At the multivariable analysis of the 207 nodules undergoing MITA, RFA was associated with worse local Recurrence Free Survival (lRFS) than MWA (HR 2.87 [95 % CI 0.96–8.66], p = 0.05), as well as a concomitant surgical resection (HR 3.89 [95 % CI 1.06–9.77], p = 0.02). A concomitant surgical resection showed worse lRFS in the subgroup analysis of both HCC (HR 3.98 [95 % CI 1.16–13.62], p = 0.02) and CRLM patients (HR 2.68 [95 % CI 0.66–5.92], p = 0.04). Interestingly, a tumor size between 30 and 40 mm was not associated to worse lRFS. MWA may reduce the risk of local recurrence in comparison to RFA, while MITA associated to liver resection may face an increased risk of local recurrence. Further prospective studies are needed to confirm such results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Pan-European survey on current treatment strategies in patients with upfront resectable colorectal liver metastases.
- Author
-
Kuiper, Babette I., Abu Hilal, Mohammad, Aldrighetti, Luca A., Björnsson, Bergthor, D'Hondt, Mathieu, Dopazo, Cristina, Fretland, Åsmund A., Isoniemi, Helena, Philip Jonas, J., Kazemier, Geert, Lesurtel, Mickael, Primrose, John, Schnitzbauer, Andreas A., Buffart, Tineke, Gruenberger, Birgit, Swijnenburg, Rutger-Jan, and Gruenberger, Thomas
- Subjects
- *
COLORECTAL liver metastasis , *PORTAL vein surgery - Abstract
There is a lack of consensus on the definition of upfront resectability and use of perioperative systemic therapy for colorectal liver metastases (CRLM). This survey aimed to summarize the current treatment strategies for upfront resectable CRLM throughout Europe. A survey was sent to all members of the European-African Hepato-Pancreato-Biliary Association to gain insight into the current views on resectability and the use of systemic therapy for upfront resectable CRLM. The survey was completed by 87 surgeons from 24 countries. The resectability of CRLM is mostly based on the volume of the future liver remnant, while considering tumor biology. Thermal ablation was considered as an acceptable adjunct to resection in parenchymal-sparing CRLM surgery by 77 % of the respondents. A total of 40.2 % of the respondents preferred standard perioperative systemic therapy and 24.1 % preferred standard upfront local treatment. Among the participating European hepato-pancreato-biliary surgeons, there is a high degree of consensus on the definition of CRLM resectability. However, there is much variety in the use of adjunctive thermal ablation. Major variations persist in the use of perioperative systemic therapy in cases of upfront resectable CRLM, stressing the need for further evidence and a consensus. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.